Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

15.20
+0.22001.47%
Post-market: 15.19-0.0100-0.07%16:19 EDT
Volume:115.56K
Turnover:1.76M
Market Cap:1.95B
PE:-20.65
High:15.37
Open:15.11
Low:15.08
Close:14.98
52wk High:21.50
52wk Low:9.88
Shares:128.30M
Float Shares:78.65M
Volume Ratio:0.71
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7359
EPS(LYR):-0.8457
ROE:-18.22%
ROA:-6.16%
PB:3.39
PE(LYR):-17.97

Loading ...

Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF), Mesoblast Limited (OtherMEOBF) and Ramsay Health Care (OtherRMSYF)

TIPRANKS
·
Mar 02

Mesoblast Earnings Call: Ryoncil Momentum Meets Rising Costs

TIPRANKS
·
Feb 28

Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate

Benzinga
·
Feb 27

BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million

Reuters
·
Feb 27

Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline

Dow Jones
·
Feb 27

Mesoblast Updates Investors on 2025 Results and Operational Outlook

TIPRANKS
·
Feb 27

Mesoblast Files Form 6-K Providing Interim Financial and Risk Disclosures

TIPRANKS
·
Feb 27

Mesoblast Posts Narrower Fiscal H1 Loss, Higher Revenue

MT Newswires Live
·
Feb 27

Mesoblast Ltd - Sees Full-Year Fiscal 2026 Ryoncil Net Revenue to Range Between US$110 Million and US$120 Million

THOMSON REUTERS
·
Feb 27

Mesoblast Ltd - Hy Total Revenues $51.3 Mln

THOMSON REUTERS
·
Feb 27

Mesoblast Ltd expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Feb 25

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire
·
Feb 20

Mesoblast to Present Half-Year Results as It Expands Global Cell Therapy Portfolio

TIPRANKS
·
Feb 20

Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial

TIPRANKS
·
Feb 12

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

GlobeNewswire
·
Feb 12

Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%

MT Newswires Live
·
Feb 09

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO) and Mesoblast Limited (OtherMEOBF)

TIPRANKS
·
Jan 30

Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%

MT Newswires Live
·
Jan 29

Ryoncil® Net Revenues Increase for the Quarter to US$30M

GlobeNewswire
·
Jan 29

Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting

MT Newswires Live
·
Jan 27